CSIMarket
 


Alx Oncology Holdings Inc  (ALXO)
Other Ticker:  
 

Alx Oncology Holdings Inc's Leverage Ratio

ALXO's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 54.5%, Leverage Ratio fell to 0.3, a new company high.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 202 other companies have achieved lower Leverage Ratio than Alx Oncology Holdings Inc in the III Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 249 to 727 .

Explain Leverage Ratio?
Who are ALXO Customers?
What are ALXO´s Total Liabilities?


ALXO Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change -41.19 % -32.76 % -30.04 % -27.43 % -25.5 %
Y / Y Total Liabilities Change 67.14 % 11.92 % 102.59 % 177.51 % 137.07 %
Leverage Ratio MRQ 0.3 0.16 0.16 0.16 0.11
ALXO's Total Ranking # 727 # 249 # 285 # 303 # 260
Seq. Equity Change -20.66 % -11.52 % -8.76 % -8.19 % -9.28 %
Seq. Total Liabilities Change 54.5 % -11.95 % -12.26 % 40.03 % 3.46 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 203
Healthcare Sector # 350
Overall Market # 727


Leverage Ratio Statistics
High Average Low
0.3 0.1 0.01
(Sep 30 2023)   (Dec 31 2020)




Financial Statements
Alx Oncology Holdings Inc's Equity $ 169 Millions Visit ALXO's Balance sheet
Alx Oncology Holdings Inc's Total Liabilities $ 51 Millions Visit ALXO's Balance sheet
Source of ALXO's Sales Visit ALXO's Sales by Geography


Cumulative Alx Oncology Holdings Inc's Leverage Ratio

ALXO's Leverage Ratio for the trailling 12 Months

ALXO Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth -41.19 % -32.76 % -30.04 % -27.43 % -25.5 %
Y / Y Total Liabilities TTM Growth 67.14 % 11.92 % 102.59 % 177.51 % 137.07 %
Leverage Ratio TTM 0.19 0.14 0.13 0.1 0.07
Total Ranking TTM # 379 # 311 # 288 # 241 # 170
Seq. Equity TTM Growth -20.66 % -11.52 % -8.76 % -8.19 % -9.28 %
Seq. Total Liabilities TTM Growth 54.5 % -11.95 % -12.26 % 40.03 % 3.46 %


On the trailing twelve months basis Due to the net new borrowings of 54.5% during the trailing twelve months finishing in the III Quarter 2023, cumulativeLeverage Ratio improved to 0.19, above the Alx Oncology Holdings Inc's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry ALXO recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 2 to 599.

Explain Leverage Ratio?
Who are ALXO Customers?
What are ALXO´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 727


trailing twelve months Leverage Ratio Statistics
High Average Low
0.22 0.11 0.03
(Mar 31 2021)   (Sep 30 2021)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Avadel Pharmaceuticals Plc  0.84 $ 92.035  Millions$ 110.149  Millions
Novabay Pharmaceuticals Inc   0.83 $ 5.815  Millions$ 7.037  Millions
Acurx Pharmaceuticals inc   0.82 $ 3.223  Millions$ 3.935  Millions
First Wave Biopharma Inc   0.81 $ 2.648  Millions$ 3.279  Millions
Rhythm Pharmaceuticals inc   0.79 $ 156.725  Millions$ 197.474  Millions
Geovax Labs Inc   0.78 $ 7.082  Millions$ 9.119  Millions
Abvc Biopharma Inc   0.77 $ 6.985  Millions$ 9.062  Millions
Innoviva Inc   0.77 $ 481.901  Millions$ 627.493  Millions
Neximmune Inc   0.76 $ 6.308  Millions$ 8.254  Millions
Cartesian Therapeutics Inc   0.76 $ 45.705  Millions$ 60.329  Millions
Macrogenics Inc   0.75 $ 145.992  Millions$ 193.980  Millions
Acadia Pharmaceuticals Inc   0.75 $ 270.366  Millions$ 362.174  Millions
Hutchmed china Limited  0.74 $ 549.232  Millions$ 743.387  Millions
Gain Therapeutics inc  0.71 $ 5.182  Millions$ 7.331  Millions
Vyne Therapeutics Inc   0.67 $ 7.762  Millions$ 11.505  Millions
Guardion Health Sciences Inc   0.67 $ 5.176  Millions$ 7.702  Millions
Organogenesis Holdings Inc   0.67 $ 185.782  Millions$ 276.865  Millions
Vincerx Pharma Inc   0.67 $ 10.535  Millions$ 15.741  Millions
Generation Bio Co   0.64 $ 149.578  Millions$ 231.914  Millions
Salarius Pharmaceuticals inc   0.64 $ 3.868  Millions$ 6.084  Millions
Prophase Labs Inc   0.63 $ 35.282  Millions$ 56.428  Millions
Alkermes Plc   0.62 $ 845.096  Millions$ 1,355.583  Millions
Cue Biopharma Inc   0.62 $ 26.330  Millions$ 42.666  Millions
Harmony Biosciences Holdings inc   0.62 $ 296.434  Millions$ 481.332  Millions
Scynexis Inc   0.61 $ 56.555  Millions$ 91.991  Millions
Revelation Biosciences Inc   0.61 $ 5.400  Millions$ 8.819  Millions
Nature s Sunshine Products inc   0.61 $ 93.002  Millions$ 152.011  Millions
Dynavax Technologies Corporation  0.61 $ 368.017  Millions$ 604.916  Millions
Gt Biopharma Inc   0.60 $ 6.051  Millions$ 10.005  Millions
Earth Science Tech Inc   0.57 $ 1.108  Millions$ 1.934  Millions

Date modified: 2023-11-14T22:02:51+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com